US Patent

US12447149 — Formulations of vimseltinib

Formulation · Assigned to Deciphera Pharmaceuticals LLC · Expires 2044-12-06 · 19y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of vimseltinib, specifically an oral dosage form containing the crystalline dihydrate form in certain amounts.

USPTO Abstract

Described herein, in part, are pharmaceutically acceptable formulations comprising a compound represented by Formula (I) and methods of preparing and using the formulations:

Drugs covered by this patent

Romvimza (VIMSELTINIB) · Deciphera Pharms

Patent Metadata

Patent number: US12447149
Jurisdiction: US
Classification: Formulation
Expires: 2044-12-06
Drug substance claim: No
Drug product claim: Yes
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.